A proposed clinical translation of these observations is the introduction of a scoring system designated Immunoscore measured by immunohistochemistry techniques and based on the enumeration of 2 lymphocyte populations (CD3/CD8) in the core of the tumor and in the invasive margin [11]. The gene discussed is CD8A; the disease is neoplasm.